HEADER HYDROLASE/HYDROLASE INHIBITOR 20-SEP-02 1MTB TITLE VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL TITLE 2 INSIGHTS FOR BETTER ANTIVIRAL THERAPY COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE RETROPEPSIN; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: HIV-1 PROTEASE; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 OTHER_DETAILS: COMPLEXED WITH SAQUINAVIR, RO 31-8959; FDA APPROVED COMPND 9 HIV-1 PROTEASE INHIBITOR SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 EXPRESSION_SYSTEM_STRAIN: TAP106; SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 8 EXPRESSION_SYSTEM_PLASMID: PXC35-PEN18 KEYWDS HIV-1 PROTEASE, DRUG RESISTANCE, SUBSTRATE RECOGNITION, INHIBITOR KEYWDS 2 BINDING, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR M.PRABU-JEYABALAN,E.A.NALIVAIKA,N.M.KING,C.A.SCHIFFER REVDAT 8 29-MAY-24 1MTB 1 COMPND REMARK HET HETNAM REVDAT 8 2 1 HETSYN FORMUL LINK SITE REVDAT 8 3 1 ATOM REVDAT 7 13-MAR-24 1MTB 1 COMPND SOURCE REVDAT 6 14-FEB-24 1MTB 1 LINK REVDAT 5 27-OCT-21 1MTB 1 REMARK SEQADV LINK REVDAT 4 11-OCT-17 1MTB 1 REMARK REVDAT 3 13-JUL-11 1MTB 1 VERSN REVDAT 2 24-FEB-09 1MTB 1 VERSN REVDAT 1 07-JAN-03 1MTB 0 JRNL AUTH M.PRABU-JEYABALAN,E.A.NALIVAIKA,N.M.KING,C.A.SCHIFFER JRNL TITL VIABILITY OF DRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS JRNL TITL 2 TYPE 1 PROTEASE VARIANT: STRUCTURAL INSIGHTS FOR BETTER JRNL TITL 3 ANTIVIRAL THERAPY JRNL REF J.VIROL. V. 77 1305 2003 JRNL REFN ISSN 0022-538X JRNL PMID 12502847 JRNL DOI 10.1128/JVI.77.2.1306-1315.2003 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.PRABU-JEYABALAN,E.A.NALIVAIKA,C.A.SCHIFFER REMARK 1 TITL HOW DOES A SYMMETRIC DIMER RECOGNIZE AN ASYMMETRIC REMARK 1 TITL 2 SUBSTRATE? A SUBSTRATE COMPLEX OF HIV-1 PROTEASE REMARK 1 REF J.MOL.BIOL. V. 301 1207 2000 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.2000.4018 REMARK 1 REFERENCE 2 REMARK 1 AUTH M.PRABU-JEYABALAN,E.A.NALIVAIKA,C.A.SCHIFFER REMARK 1 TITL SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION FOR REMARK 1 TITL 2 HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX REMARK 1 TITL 3 SUBSTRATE COMPLEXES REMARK 1 REF STRUCTURE V. 10 369 2002 REMARK 1 REFN ISSN 0969-2126 REMARK 1 DOI 10.1016/S0969-2126(02)00720-7 REMARK 1 REFERENCE 3 REMARK 1 AUTH N.M.KING,L.MELNICK,M.PRABU-JEYABALAN,E.A.NALIVAIKA, REMARK 1 AUTH 2 S.-S.YANG,Y.GAO,X.NIE,C.ZEPP,D.L.HEEFNER,C.A.SCHIFFER REMARK 1 TITL LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG REMARK 1 TITL 2 RESISTANT HIV-1 PROTEASE REMARK 1 REF PROTEIN SCI. V. 11 418 2002 REMARK 1 REFN ISSN 0961-8368 REMARK 1 DOI 10.1110/PS.2520102 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 26.56 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 93.4 REMARK 3 NUMBER OF REFLECTIONS : 6743 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.191 REMARK 3 FREE R VALUE : 0.257 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.800 REMARK 3 FREE R VALUE TEST SET COUNT : 670 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.010 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.59 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 71.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 411 REMARK 3 BIN R VALUE (WORKING SET) : 0.3000 REMARK 3 BIN FREE R VALUE : 0.3600 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 11.20 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 52 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.062 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1450 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 49 REMARK 3 SOLVENT ATOMS : 40 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 33.30 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 42.90 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -9.16000 REMARK 3 B22 (A**2) : 1.87000 REMARK 3 B33 (A**2) : 7.29000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.41 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.53 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.300 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 26.50 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.950 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.34 REMARK 3 BSOL : 57.02 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : SAQ.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : SAQ.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1MTB COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 27-SEP-02. REMARK 100 THE DEPOSITION ID IS D_1000017168. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 08-AUG-01 REMARK 200 TEMPERATURE (KELVIN) : 298 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : YALE MIRRORS REMARK 200 OPTICS : YALE MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : R-AXIS REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 6743 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 26.600 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 93.4 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.09000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 7.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.59 REMARK 200 COMPLETENESS FOR SHELL (%) : 71.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.33000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: 1F7A REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 44.48 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.22 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SODIUM PHOSPHATE, SODIUM CITRATE, REMARK 280 AMMONIUM SULPHATE, PH 6.2, VAPOR DIFFUSION, HANGING DROP AT 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.71950 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 31.01050 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 30.01950 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 31.01050 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.71950 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 30.01950 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE ENTIRE DIMER IS PROVIDED IN THE COORDINATE SET AND THE REMARK 300 MONOMERS ARE DISTINGUISHED BY THE CHAIN IDS `A' AND `B' + RO 31- REMARK 300 8959 (HIV-1 PROTEASE INHIBITOR SAQUINAVIR) REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5460 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8860 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -13.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 7 CG CD OE1 NE2 REMARK 470 ARG A 14 CG CD NE CZ NH1 NH2 REMARK 470 LYS A 20 CG CD CE NZ REMARK 470 GLU A 34 CG CD OE1 OE2 REMARK 470 LYS A 41 CG CD CE NZ REMARK 470 LYS A 43 CG CD CE NZ REMARK 470 LYS A 55 CG CD CE NZ REMARK 470 LYS A 70 CG CD CE NZ REMARK 470 VAL A 82 CG1 CG2 REMARK 470 GLN B 7 CG CD OE1 NE2 REMARK 470 GLN B 18 CG CD OE1 NE2 REMARK 470 LYS B 41 CG CD CE NZ REMARK 470 LYS B 43 CG CD CE NZ REMARK 470 LYS B 45 CG CD CE NZ REMARK 470 LYS B 55 CG CD CE NZ REMARK 470 LYS B 70 CG CD CE NZ REMARK 470 VAL B 82 CG1 CG2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLN A 61 60.16 37.78 REMARK 500 CYS A 67 56.77 37.21 REMARK 500 PRO A 79 67.35 -64.84 REMARK 500 REMARK 500 REMARK: NULL REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE INHIBITOR REMARK 630 MOLECULE NAME: (2S)-N-[(2S,3R)-4-[(2S,3S,4AS,8AS)-3-(TERT- REMARK 630 BUTYLCARBAMOYL)-3,4,4A,5,6,7,8,8A-OCTAHYDRO-1H-ISOQUINOLIN-2-YL]-3- REMARK 630 HYDROXY-1 -PHENYL-BUTAN-2-YL]-2-(QUINOLIN-2-YLCARBONYLAMINO) REMARK 630 BUTANEDIAMIDE REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 ROC A 100 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: QNC ASN HP0 NTB REMARK 630 DETAILS: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE QNC A 100 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ASN A 101 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HPH A 102 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE DIQ B 100 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NTB B 101 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1F7A RELATED DB: PDB REMARK 900 INACTIVE WILD-TYPE HIV-1 PROTEASE (D25N) COMPLEXED WITH ITS GAG REMARK 900 SUBSTRATE PEPTIDE CA-P2 REMARK 900 RELATED ID: 1HXB RELATED DB: PDB REMARK 900 WILD-TYPE HIV-1 PROTEINASE COMPLEXED WITH RO 31-8959 (SAQUINAVIR) REMARK 900 RELATED ID: 1MT7 RELATED DB: PDB REMARK 900 RELATED ID: 1MT8 RELATED DB: PDB REMARK 900 RELATED ID: 1MT9 RELATED DB: PDB DBREF 1MTB A 1 99 UNP P03369 POL_HV1A2 57 155 DBREF 1MTB B 1 99 UNP P03369 POL_HV1A2 57 155 SEQADV 1MTB ASN A 25 UNP P03369 ASP 81 ENGINEERED MUTATION SEQADV 1MTB ASN B 25 UNP P03369 ASP 81 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 A 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASN THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 A 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 A 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 B 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASN THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 B 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 B 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY CYS THR LEU ASN PHE HET ROC A 100 49 HETNAM ROC (2S)-N-[(2S,3R)-4-[(2S,3S,4AS,8AS)-3-(TERT- HETNAM 2 ROC BUTYLCARBAMOYL)-3,4,4A,5,6,7,8,8A-OCTAHYDRO-1H- HETNAM 3 ROC ISOQUINOLIN-2-YL]-3-HYDROXY-1 -PHENYL-BUTAN-2-YL]-2- HETNAM 4 ROC (QUINOLIN-2-YLCARBONYLAMINO)BUTANEDIAMIDE HETSYN ROC FORTOVASE; SAQUINAVIR; RO 31-8959 FORMUL 3 ROC C38 H50 N6 O5 FORMUL 4 HOH *40(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLN A 92 GLY A 94 5 3 HELIX 3 3 GLY B 86 THR B 91 1 6 HELIX 4 4 GLN B 92 GLY B 94 5 3 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 O THR A 96 N ASN B 98 SHEET 4 A 4 GLN B 2 ILE B 3 -1 N ILE B 3 O LEU A 97 SHEET 1 B 3 LEU A 10 VAL A 11 0 SHEET 2 B 3 ALA A 22 LEU A 24 -1 N ALA A 22 O VAL A 11 SHEET 3 B 3 ILE A 84 ILE A 85 1 N ILE A 85 O LEU A 23 SHEET 1 C 5 THR A 31 LEU A 33 0 SHEET 2 C 5 HIS A 69 VAL A 77 1 O THR A 74 N THR A 31 SHEET 3 C 5 GLY A 52 ILE A 66 -1 N ARG A 57 O VAL A 77 SHEET 4 C 5 ILE A 13 ILE A 15 -1 N ARG A 14 O GLU A 65 SHEET 5 C 5 GLN A 18 LEU A 19 -1 O GLN A 18 N ILE A 15 SHEET 1 D 4 THR A 31 LEU A 33 0 SHEET 2 D 4 HIS A 69 VAL A 77 1 O THR A 74 N THR A 31 SHEET 3 D 4 GLY A 52 ILE A 66 -1 N ARG A 57 O VAL A 77 SHEET 4 D 4 LYS A 43 GLY A 49 -1 O LYS A 43 N GLN A 58 SHEET 1 E 3 LEU B 10 VAL B 11 0 SHEET 2 E 3 ALA B 22 LEU B 24 -1 N ALA B 22 O VAL B 11 SHEET 3 E 3 ILE B 84 ILE B 85 1 N ILE B 85 O LEU B 23 SHEET 1 F 5 THR B 31 LEU B 33 0 SHEET 2 F 5 HIS B 69 VAL B 77 1 O THR B 74 N THR B 31 SHEET 3 F 5 GLY B 52 ILE B 66 -1 N ARG B 57 O VAL B 77 SHEET 4 F 5 ILE B 13 ILE B 15 -1 N ARG B 14 O GLU B 65 SHEET 5 F 5 GLN B 18 LEU B 19 -1 O GLN B 18 N ILE B 15 SHEET 1 G 4 THR B 31 LEU B 33 0 SHEET 2 G 4 HIS B 69 VAL B 77 1 O THR B 74 N THR B 31 SHEET 3 G 4 GLY B 52 ILE B 66 -1 N ARG B 57 O VAL B 77 SHEET 4 G 4 LYS B 43 GLY B 49 -1 O LYS B 43 N GLN B 58 SITE 1 AC1 7 TRP A 6 GLY A 27 ALA A 28 ASP A 29 SITE 2 AC1 7 GLY A 48 HOH A 117 ARG B 8 SITE 1 AC2 4 ASP A 30 ILE A 47 GLY A 48 HOH A 107 SITE 1 AC3 6 ASN A 25 GLY A 27 GLY A 49 ILE A 50 SITE 2 AC3 6 ASN B 25 PRO B 81 SITE 1 AC4 5 ASN A 25 PRO A 81 HOH A 107 ASN B 25 SITE 2 AC4 5 GLY B 27 SITE 1 AC5 2 GLY B 48 HOH B 106 CRYST1 51.439 60.039 62.021 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019441 0.000000 0.000000 0.00000 SCALE2 0.000000 0.016656 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016124 0.00000